Immunothrombosis and Complement Activation Contribute to Disease Severity and Adverse Outcome in COVID-19
Journal of Innate Immunity · 2023 · 15 (1) · 850-864
DOI: 10.1159/000533339 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Innate Immunity, online erschienen am 08.11.2023. Verfasst von Tiphaine Ruggeri und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland. Hauptthemen laut MEDLINE: COVID-19, Thrombosis, Extracellular Traps, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 12-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Severe COVID-19 is characterized by systemic inflammation and multiple organ dysfunction syndrome (MODS). Arterial and venous thrombosis are involved in the pathogenesis of MODS and fatality in COVID-19. There is evidence that complement and neutrophil activation in the form of neutrophil extracellular traps are main drivers for development of microvascular complications in COVID-19. Plasma and serum samples were collected from 83 patients infected by SARS-CoV-2 during the two first waves of COVID-19, before the availability of SARS-CoV-2 vaccination. Samples were collected at enrollment, day 11, and day 28; and patients had differing severity of disease. In this comprehensive study, we measured cell-free DNA, neutrophil activation, deoxyribonuclease I activity, complement activation, and D-dimers in longitudinal samples of COVID-19 patients. We show that all the above markers, except deoxyribonuclease I activity, increased with disease severity. Moreover, we provide evidence that in severe disease there is continued neutrophil and complement activation, as well as D-dimer formation and nucleosome release, whereas in mild and moderate disease all these markers decrease over time. These findings suggest that neutrophil and complement activation are important drivers of microvascular complications and that they reflect immunothrombosis in these patients. Neutrophil activation, complement activation, cell-free DNA, and D-dimer levels have the potential to serve as reliable biomarkers for disease severity and fatality in COVID-19. They might also serve as suitable markers with which to monitor the efficacy of therapeutic interventions in COVID-19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland.
- Department for BioMedical Research, University of Bern, Bern, Switzerland.
- Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands.
- Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
- Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, Cedric.Hirzel@insel.ch.
- Department of Hematology, Kantonsspital Luzern, Lucerne and University of Bern, Bern, Switzerland.
Zitieren
APA
Ruggeri, T., De Wit, Y., Schärz, N., van Mierlo, G., Angelillo-Scherrer, A., Brodard, J., Schefold, J. C., Hirzel, C., Jongerius, I., & Zeerleder, S. (2023). Immunothrombosis and Complement Activation Contribute to Disease Severity and Adverse Outcome in COVID-19. Journal of Innate Immunity, 15(1), 850-864. https://doi.org/10.1159/000533339
Vancouver
Ruggeri T, De Wit Y, Schärz N, van Mierlo G, Angelillo-Scherrer A, Brodard J, et al. Immunothrombosis and Complement Activation Contribute to Disease Severity and Adverse Outcome in COVID-19. Journal of Innate Immunity. 2023;15(1):850-864. doi:10.1159/000533339
BibTeX
@article{Ruggeri2023,
author = {Ruggeri, Tiphaine and De Wit, Yasmin and Schärz, Noëlia and van Mierlo, Gerard and Angelillo-Scherrer, Anne and Brodard, Justine and Schefold, Joerg C and Hirzel, Cédric and Jongerius, Ilse and Zeerleder, Sacha},
title = {Immunothrombosis and Complement Activation Contribute to Disease Severity and Adverse Outcome in COVID-19},
journal = {Journal of Innate Immunity},
year = {2023},
volume = {15},
number = {1},
pages = {850--864},
doi = {10.1159/000533339}
}
EUVIMED